AXSM Axsome Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AXSM matters now
Axsome Therapeutics, Inc. (AXSM) is a US stock in Healthcare. The latest InvestLog snapshot shows $233.80 with -6.09% on the session and $12.03B in market capitalization; recent performance reads 1-month +10.51% and YTD +37.16%.
The latest financial table shown here is Q1 2026, with revenue of $191.2M, net income of $-64.5M, and EPS of $-1.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.6%.
The latest indexable market news headline is "3 Under-the-Radar Stocks to Buy and Hold" from The Motley Fool.
Additional event context on this page matters because analyst consensus is Buy with a median target of $259.50; recent insider activity includes JEFFS ROGER filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
234.95
P/S
18.20
EV/EBITDA
-74.14
DCF Value
$-467.88
FCF Yield
-0.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.6%
Operating Margin
-24.8%
Net Margin
-26.6%
ROE
-260.0%
ROA
-26.4%
ROIC
-50.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $191.2M | $-64.5M | $-1.26 |
| Q4 2025 | $196.0M | $-28.6M | $-0.56 |
| FY 2025 | $638.5M | $-183.2M | $-3.68 |
| Q3 2025 | $171.0M | $-47.2M | $-0.94 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$262.38
Target (Median)
$259.50
Target Range
$200.00 - $380.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.60
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.